Professor of Medicine, Harvard Medical School
Beth Israel Deaconess Medical Center
Contact details
Harvard Medical School
Telephone: (617) 667-8630
Fax: (617) 667-8634
Email: cmantzor(@)bidmc.harvard.edu
EDUCATIONAL TITLES
- Professor, Medicine, Harvard Medical School
- Director Human Nutrition Unit, Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center
- Chief, Endocrinology, VA Boston Healthcare System
DF/HCC PROGRAM AFFILIATION
- Prostate Cancer, Member
Biography
My research program focuses on obesity, diabetes and adipokine biology. My basic research efforts utilize genomics-bioinformatics, animal physiology, and molecular biology studies to elucidate the role of new molecules important in energy homeostasis. My current translational /clinical investigations focus mainly on the role of metabolically important hormones, including leptin, irisin and adiponectin as well as their downstream effectors, on energy homeostasis and metabolic abnormalities. Our work spans the entire spectrum from animal physiology and molecular biology, through observational studies, to physiology and pharmacokinetic interventional proof of concept clinical trials in humans on new therapeutic agents important in the treatment of the above disorders. Recent major contributions by my research group include the elucidation of the physiological role and potential diagnostic and
therapeutic utility of leptin in human physiology and pathophysiology. We were the first to prove the role of leptin in mediating the neuroendocrine response to food deprivation in rodents and later in humans, and the first to publish leptin pharmacokinetic studies in humans. We also were the first to publish proof-of-concept studies demonstrating the role of leptin in the etiology and therapy of conditions such as exercise-induced amenorrhea and HIV-induced lipoatrophy. We have recently extended these findings with further randomized clinical trials and combination therapies. Our work has resulted in more than 475 Scientific papers in Medline, more than 133 reviews and chapters, and two books with more than two editions each. These papers have received more than 25,000 citations in Thompson Reuters and more than 35,000 citations in Google scholar, with an H-index of 102. In addition, two start-up companies have been established, Intekrin Inc. and Pangea Inc.